Journal of pharmacy practice最新文献_第8页

Impact of Changing Migraine Outcome on Pharmacist Interventions in a Health-System Specialty Pharmacy. 改变偏头痛结局对卫生系统专业药房药师干预的影响。

IF 1

Journal of pharmacy practice Pub Date : 2026-07-16 DOI: 10.1177/08971900261469298

Megan Markesbery, Emily O'Reilly, Chelsey McPheeters

{"title":"Impact of Changing Migraine Outcome on Pharmacist Interventions in a Health-System Specialty Pharmacy.","authors":"Megan Markesbery, Emily O'Reilly, Chelsey McPheeters","doi":"10.1177/08971900261469298","DOIUrl":"https://doi.org/10.1177/08971900261469298","url":null,"abstract":"Health-system specialty pharmacies (HSSPs) provide specialized medication therapy management to patients with complex medical conditions. HSSPs assess clinical outcomes for specialty disease states, including migraines. There are currently no studies comparing types of outcomes for patients with migraines and the impact on pharmacist intervention in HSSPs. The aim of this study was to determine if changing migraine outcome from a non-disease specific patient reported outcome measure (PROM) to a disease specific patient reported outcome (PRO) impacts the number of pharmacist interventions made on migraine regimens in a HSSP. A single-center, pre-post, retrospective chart review was conducted at a HSSP. Adult patients who received at least one abortive specialty migraine medication and/or at least three preventative specialty migraine medication fills were included in the study. The primary endpoint was the number of pharmacist interventions regarding pharmacologic migraine regimens before and after the outcome change. Key secondary endpoints included change in number of migraine days per month, change in number of missed days from school, work or planned activities, number of migraine episodes requiring hospitalization, and overall number of pharmacist interventions. There were 61 patients included in the study. The number of pharmacist interventions on migraine regimens was no difference between the migraine PROs group (15.2%) when compared to the PROM group (13.5%; P = 0.715). Utilizing either non-disease specific PROM or disease-specific PROs as a clinical outcome measure for HSSP migraine patients could be valuable, with the latter shifting pharmacist interventions toward migraine pharmacotherapy optimization.","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"8971900261469298"},"PeriodicalIF":1.0,"publicationDate":"2026-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148471395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Low Statin Use Post-liver Transplant Despite Increased Rates of Dyslipidemia. 肝移植后低他汀类药物的使用，尽管血脂异常率增加。

IF 1

Journal of pharmacy practice Pub Date : 2026-07-13 DOI: 10.1177/08971900261469304

Sarah Blocker, Molly Henry, Mary Leick

{"title":"Low Statin Use Post-liver Transplant Despite Increased Rates of Dyslipidemia.","authors":"Sarah Blocker, Molly Henry, Mary Leick","doi":"10.1177/08971900261469304","DOIUrl":"https://doi.org/10.1177/08971900261469304","url":null,"abstract":"Previous literature has demonstrated that hyperlipidemia is common post-transplant; however, low statin utilization has been seen post-liver transplant. Furthermore, assessment of statin qualification in this setting is limited. This study's objective was to evaluate the incidence of hyperlipidemia and determine the rate of qualification for and initiation of statin therapy in liver transplant recipients to better characterize the complication and associated clinical practice behaviors. This single center, retrospective cohort study included adult patients who received an isolated liver transplant between January 1, 2015 and June 30, 2019 and had lipid panels within 15 months pre- and post-transplant. The dual primary outcomes were the incidences of hyperlipidemia and statin qualification, as determined by 2012 AASLD and 2018 ACC/AHA guidance. Secondary outcomes included statin use and tolerability, hypertriglyceridemia, and immunosuppression factors. Of the 282 patients screened, 79 patients were included. Compared to pre-transplant, incidences of hyperlipidemia and statin qualification were both increased post-transplant (hyperlipidemia: 21.5% vs 49.4%, P = 0.0003; statin qualification: 46.8% vs 64.6%, P = 0.025). Of the 51 statin-qualifying patients post-transplant, twenty-two (43%) received statin therapy. One patient experienced muscle aches requiring statin discontinuation. Hypertriglyceridemia was more common post-transplant than pre-transplant (11.4% vs 60.8%, P < 0.0001). Of patients on tacrolimus, 58% qualified for statin therapy compared to 93% of patients on an mTOR inhibitor. Nearly two-thirds of liver transplant recipients qualify for statin therapy post-transplant. Despite increased rates of dyslipidemia and statin qualification post-liver transplant, statin therapy remains underutilized. Optimization of lipid management remains an area of need post-liver transplant.","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"8971900261469304"},"PeriodicalIF":1.0,"publicationDate":"2026-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148437001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of a Specialized Pharmacist-Managed Gout Clinic in a Veteran Population. 在退伍军人群体中由专业药剂师管理的痛风诊所的评价。

IF 1

Journal of pharmacy practice Pub Date : 2026-07-08 DOI: 10.1177/08971900261468840

Brian S Chen, My-Hanh N Nguyen, Timothy C Chen

{"title":"Evaluation of a Specialized Pharmacist-Managed Gout Clinic in a Veteran Population.","authors":"Brian S Chen, My-Hanh N Nguyen, Timothy C Chen","doi":"10.1177/08971900261468840","DOIUrl":"https://doi.org/10.1177/08971900261468840","url":null,"abstract":"Background: Gout is the most common inflammatory arthritis, and the underlying cause of gout, chronic elevation of serum uric acid (sUA), is well understood. Despite this, only a minority of patients receive optimal therapy as it requires adherence to frequent lab monitoring and urate lowering therapy (ULT) titration to achieve target goals. Objective: To evaluate the effectiveness of the pharmacist-managed gout clinic at VA San Diego Healthcare System (VASDHS) in lowering sUA. Methods: This was a single center, retrospective chart review of all Veterans enrolled in the pharmacy gout clinic from January 1, 2017, to December 31, 2021, comparing baseline and final sUA. The primary outcome was reduction of sUA from baseline. Results: There was statistically significant reduction of sUA from baseline at months 3, 6, 9, and 12, with average sUA levels of 6.8 ± 1.7 mg/dL, 6.4 ± 1.5 mg/dL, 6.0 ± 1.6 mg/dL, and 6.1 ± 2.2 mg/dL, respectively (P < 0.001 for all values). Conclusion: This study suggests that the pharmacist-managed gout clinic can effectively lower and maintain sUA levels through the treat-to-target approach. Though the results of this study showed statistically significant sUA reduction, most patients did not reach their sUA goals by the end of the study. However, this finding may not be clinically relevant as patients can be above their sUA goal and still be gout flare free or have low frequency of flares.","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"8971900261468840"},"PeriodicalIF":1.0,"publicationDate":"2026-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148411620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Low Dose Sucralfate Associated With Significantly Reduced Warfarin INR Response: A Case Report. 低剂量硫糖钠与显著降低华法林INR反应相关：一例报告。

IF 1

Journal of pharmacy practice Pub Date : 2026-07-08 DOI: 10.1177/08971900261469308

Randolph E Regal, Sarah K Adie

{"title":"Low Dose Sucralfate Associated With Significantly Reduced Warfarin INR Response: A Case Report.","authors":"Randolph E Regal, Sarah K Adie","doi":"10.1177/08971900261469308","DOIUrl":"https://doi.org/10.1177/08971900261469308","url":null,"abstract":"Sucralfate is a medication that is a chemical complex consisting of aluminum hydroxide and sulfated sucrose. It has been found to cause malabsorption of many different medications, including warfarin, by chelating the drugs within the gastrointestinal (GI) lumen. To minimize potential malabsorption interactions, it is recommended that there be at least a two-hour separation between administration of sucralfate and the second drug. This case report involved a hospitalized patient who was also monitored once discharged, then rechallenged and de-challenged with low dose sucralfate at doses of only 1 gram once daily or 1g twice daily. The case showed that warfarin requirements approximately doubled when the drugs were used concomitantly vs warfarin alone. When the medications were given in the first hospitalization, once daily sucralfate was given at 0900 and warfarin at 2100. Thus, even though the drugs were being separated by about 12 hours, it appears the interaction still manifested. When sucralfate was increased to twice daily in the second hospitalization, it was dosed at 0900 and 2100. Of course, warfarin was also given at 2100 each day for the second admission. Around both hospitalizations, the challenge with sucralfate resulted in subtherapeutic warfarin levels, thereby necessitating dose escalation well above \"pre-sucralfate\" doses to achieve International Normalized Ratios (INRs) in the therapeutic range of 2-3 for this patient. Also, around both hospitalizations, de-challenge of sucralfate resulted in INRs becoming supratherapeutic in just 2-3 days, yielding INRs of 8.1 after the first discharge and 5.4 after the second discharge.","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"8971900261469308"},"PeriodicalIF":1.0,"publicationDate":"2026-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148411628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Aripiprazole and Unexpected Salivation: A Case of Drug-Induced Sialorrhea Refractory to Anticholinergics. 阿立哌唑与意外流涎：抗胆碱能药难治性药物性唾液漏一例。

IF 1

Journal of pharmacy practice Pub Date : 2026-06-29 DOI: 10.1177/08971900261466364

Charlie Yang, Keren Eagers, Desiree Kosmisky, Kristen Nagy

{"title":"Aripiprazole and Unexpected Salivation: A Case of Drug-Induced Sialorrhea Refractory to Anticholinergics.","authors":"Charlie Yang, Keren Eagers, Desiree Kosmisky, Kristen Nagy","doi":"10.1177/08971900261466364","DOIUrl":"https://doi.org/10.1177/08971900261466364","url":null,"abstract":"Sialorrhea, or excessive drooling, is a distressing side effect of certain antipsychotic medications, including aripiprazole, clozapine, and olanzapine. We present the case of a 53-year-old female with bipolar I disorder who presented with altered mental status, dysphagia, a 2-day history of excessive drooling, and acute hypoxic respiratory failure. Despite being alert and responsive, she required intubation due to the inability to manage oral secretions. At the time, she had been taking aripiprazole 20 mg once daily and lithium 450 mg twice daily for about three months for bipolar 1 disorder, which were continued inpatient. Aripiprazole was discontinued on the third day of hospitalization. Standard treatments for sialorrhea, including anticholinergics such as scopolamine, glycopyrrolate, and sublingual atropine, were ineffective. Substantial improvement only occurred after the initiation of dexmedetomidine, an alpha-2 adrenergic agonist, on day nine, leading to decreased oral secretions and successful extubation. The patient was transitioned to oral clonidine, another alpha-2 adrenergic agonist, and remained extubated for the rest of her hospital stay. Upon further improvement, she was discharged on glycopyrrolate, a 3-day taper of clonidine, and trazodone, with bipolar I disorder management switched to valproic acid monotherapy. This case highlights the potential role of alpha-2 adrenergic agonists in managing refractory aripiprazole-induced sialorrhea, offering a viable alternative when traditional anticholinergic therapies are ineffective.","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"8971900261466364"},"PeriodicalIF":1.0,"publicationDate":"2026-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148345765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring Strategies to Educate Reproductive-Aged Individuals About Pharmacist-Prescribed Hormonal Contraception in Indiana: A Qualitative Study. 探索印第安纳州育龄个体关于药剂师处方激素避孕的教育策略：一项定性研究。

IF 1.1

Journal of pharmacy practice Pub Date : 2026-06-05 DOI: 10.1177/08971900261457688

Alyssa D Barnes, Alexander Wilcox, Laura Vives, Ashley H Meredith

{"title":"Exploring Strategies to Educate Reproductive-Aged Individuals About Pharmacist-Prescribed Hormonal Contraception in Indiana: A Qualitative Study.","authors":"Alyssa D Barnes, Alexander Wilcox, Laura Vives, Ashley H Meredith","doi":"10.1177/08971900261457688","DOIUrl":"https://doi.org/10.1177/08971900261457688","url":null,"abstract":"Rates of unintended pregnancy continue to remain high in the United States. Pharmacist-prescribed hormonal contraception offers an accessible option for preventing mistimed or unintended pregnancies, leading to better reproductive health outcomes. Specifically in Indiana, studies show patient interest in this service, however, overall pharmacy implementation and patient awareness has been low. This project aims to explore strategies for educating pregnancy-capable people in Indiana about the availability of pharmacist-prescribed birth control. The Social Marketing Theory guided development of a focus group/interview guide to identify themes on how best to educate pregnancy-capable individuals on pharmacist-prescribed hormonal contraception. The sessions were conducted virtually by one investigator and transcripts were analyzed by three investigators using inductive thematic analysis. Four focus groups and four interviews were conducted with a total of 12 English-speaking participants. Identified themes included Prior Understanding of Pharmacy Services, Pharmacy Service Characteristics, Knowledge or Education, and Preferred Advertising Method and Content. Results showcased that there was an overall lack of knowledge about this service and that strategies for educating the community would be through social media, pharmacy flyers, campus outreach, and health fairs. Pharmacists play a key role in addressing reproductive healthcare gaps. As new services are implemented, consideration should be given as to how best to educate the community through modalities such as social media, pharmacy flyers, campus outreach, and health fairs. Strategic community engagement for pharmacist-prescribed contraception services may help to overcome access barriers and ultimately reduce the incidence of mistimed or unwanted pregnancies in Indiana.","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"8971900261457688"},"PeriodicalIF":1.1,"publicationDate":"2026-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148163407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Retrospective Reappraisal of Labetalol's Hemodynamic Effects. 拉贝他洛尔血流动力学效应的回顾性再评价。

IF 1.1

Journal of pharmacy practice Pub Date : 2026-06-01 Epub Date: 2025-08-23 DOI: 10.1177/08971900251370870

Mary Margaret Rinker, Teresa Valadez, Renee Petzel Gimbar, Andrew Posen

{"title":"A Retrospective Reappraisal of Labetalol's Hemodynamic Effects.","authors":"Mary Margaret Rinker, Teresa Valadez, Renee Petzel Gimbar, Andrew Posen","doi":"10.1177/08971900251370870","DOIUrl":"10.1177/08971900251370870","url":null,"abstract":"Background: Labetalol is an adrenergic antagonist used to manage blood pressure. Current package labeling and drug databases describe intravenous (IV) labetalol's hemodynamic effects to have an alpha-to-beta potency relationship of 1:7, denoting a predominantly negative cardiotropic effect, which differs from our clinical experience. Objective: The purpose of this study was to describe the hemodynamic effects of IV labetalol in clinical practice and compare those results to official references. Methods: This was a retrospective, observational cohort study of patients undergoing evaluation and management for acute ischemic stroke in the emergency department. We included patients who received IV labetalol and excluded those experiencing intracerebral hemorrhage. The primary outcome was labetalol's alpha-to-beta relative clinical potency (RCP), calculated as the median ΔSBP / ΔHR, using nadir values within one hour of labetalol's administration. Results: Forty-two patients met criteria for analysis, with median age of 66 years and majority female sex (71%). Following a median dose of 10 mg, the median ΔSBP was -35 mmHg and ΔHR -9 beats per minute. The median alpha-to-beta RCP was approximately 7:2. Out of 42 patients, 10 experienced excessive reductions in SBP. This cohort exhibited neither new-onset bradycardia nor reflex tachycardia. Conclusions and Relevance: We clinically observed IV labetalol's alpha-to-beta potency ratio to be 7:2, significantly differing from the 1:7 ratio stated in official references. While this study has limitations, our findings highlight an inconsistency between real-world experience and nongeneralizable experimental results. We recommend revision of the official references that intend to guide clinician use of IV labetalol.","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"179-183"},"PeriodicalIF":1.1,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144958389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Glucagon-like Peptide-1 Receptor Agonists and Reproductive Health: Current Evidence and Clinical Implications. 胰高血糖素样肽-1受体激动剂与生殖健康：目前的证据和临床意义。

IF 1.1

Journal of pharmacy practice Pub Date : 2026-06-01 Epub Date: 2025-09-04 DOI: 10.1177/08971900251376795

Jordyn Kettner, Elizabeth Donnelly, Marina L Maes

{"title":"Glucagon-like Peptide-1 Receptor Agonists and Reproductive Health: Current Evidence and Clinical Implications.","authors":"Jordyn Kettner, Elizabeth Donnelly, Marina L Maes","doi":"10.1177/08971900251376795","DOIUrl":"10.1177/08971900251376795","url":null,"abstract":"Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have experienced rapid growth in recent years as treatments for type 2 diabetes mellitus and obesity. These medications offer promising benefits, including weight loss and improved glycemic control; however, their implications for reproductive health warrant attention. While tirzepatide has been shown to impact absorption of oral contraceptives due to delayed gastric emptying, other GLP-1RAs do not appear to have clinically significant interactions with oral contraception. Fertility outcomes may improve with GLP-1RAs and dual GLP-1/GIP agonists due to weight loss and related metabolic benefits. Despite their widespread use, data on GLP-1RAs in pregnancy and lactation remain limited, leaving significant gaps in guidance for clinicians. This review synthesizes current literature on GLP-1RAs to highlight reproductive health considerations, including their potential impacts on contraception, fertility, pregnancy, and lactation. Greater awareness and understanding of these factors can support informed decision-making and optimize care for individuals using GLP-1RAs.","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"239-250"},"PeriodicalIF":1.1,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145000853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of Bleeding and Thrombotic Outcomes of Anticoagulation Strategies Upon Intensive Care Unit Admission for Patients with Atrial Fibrillation on Direct Oral Anticoagulants. 房颤患者直接口服抗凝剂入住重症监护病房时抗凝策略的出血和血栓结局评价。

IF 1.1

Journal of pharmacy practice Pub Date : 2026-06-01 Epub Date: 2025-09-06 DOI: 10.1177/08971900251376819

Priya J Patel, Mariah I Sigala, Corey V Dinunno, Laura M Blackburn, Kevin R Donahue

{"title":"Evaluation of Bleeding and Thrombotic Outcomes of Anticoagulation Strategies Upon Intensive Care Unit Admission for Patients with Atrial Fibrillation on Direct Oral Anticoagulants.","authors":"Priya J Patel, Mariah I Sigala, Corey V Dinunno, Laura M Blackburn, Kevin R Donahue","doi":"10.1177/08971900251376819","DOIUrl":"10.1177/08971900251376819","url":null,"abstract":"Background: Critically ill adults are more commonly being admitted to intensive care units (ICU) with a recent history of direct oral anticoagulant (DOAC) use. No consensus guidance exists on optimal anticoagulation strategies in critically ill adults with non-valvular atrial fibrillation (NVAF) on DOAC's prior to ICU admission, and there is considerable variability in clinical practice. Objective: To evaluate rates of major bleeding and thrombosis between 2 anticoagulation strategies for NVAF upon ICU admission: package insert (continuation of oral or parenteral anticoagulation per manufacturer recommendations) vs non-package insert (prophylactic dosing or delayed therapeutic anticoagulation). Study design: This was a retrospective cohort study conducted from January 2019 to August 2023. Patients with NVAF and objective evidence of DOAC exposure within 48 hours of ICU admission were included. Those admitted to the ICU for a bleeding event or who received anticoagulation for indications other than NVAF were excluded. Results: A total of 353 patients met inclusion criteria (122 vs 231 in the package insert and non-package insert groups, respectively). There was no significant difference in the composite incidence of major bleeding and stroke or systemic embolism between groups (4.1% in package insert vs 6.1% in non-package insert; P = 0.437). Conclusion: This study demonstrated no difference in the incidence of major bleeding, in-hospital stroke, or systemic embolism with a package insert vs a non-package insert approach to anticoagulation in critically ill patients receiving DOAC therapy for atrial fibrillation. However, more studies are needed to develop evidence-based guidance on anticoagulation management in this population.","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"193-203"},"PeriodicalIF":1.1,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145008390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Managing Resistant Hypertension in Rural Veterans: A Pharmacist-Led Telehealth Approach. 管理顽固性高血压在农村退伍军人：药剂师主导的远程医疗方法。

IF 1.1

Journal of pharmacy practice Pub Date : 2026-06-01 Epub Date: 2025-06-26 DOI: 10.1177/08971900251356009

Jordan Burnette, Taylor Maynard

{"title":"Managing Resistant Hypertension in Rural Veterans: A Pharmacist-Led Telehealth Approach.","authors":"Jordan Burnette, Taylor Maynard","doi":"10.1177/08971900251356009","DOIUrl":"10.1177/08971900251356009","url":null,"abstract":"This case study explores the role that pharmacists can have managing resistant hypertension (RH) in rural Appalachian veterans, where health care access is limited. RH, defined as blood pressure above target despite adherence to multiple antihypertensive medications, presents challenges in chronic disease management. The Department of Veterans Affairs (VA) has integrated CPPs to improve medication adherence, reduce hospitalizations, and enhance blood pressure control, particularly in underserved areas. The patient, a 65-year-old male veteran with hypertension, obstructive sleep apnea, depression, and PTSD, had struggled with poorly controlled hypertension for years, experiencing adverse reactions to multiple antihypertensive medications. Living more than 60 minutes from the nearest VA facility, he had not seen his primary care provider since early 2021, exacerbating his condition. Despite initial reluctance to restart medications, the CPP implemented a stepwise management approach, utilizing telehealth for remote blood pressure monitoring and regular follow-ups. Over several months, pharmacologic therapy combined with lifestyle modifications led to significant blood pressure improvement. This case highlights the crucial role of CPPs in rural health care, offering accessible, continuous care and personalized management of complex conditions. Telehealth and remote monitoring further facilitated care, overcoming geographic barriers and enhancing patient engagement. The collaboration between pharmacists and specialists ensured comprehensive care and optimized treatment. This case demonstrates the potential for expanding CPP roles in rural areas to improve chronic disease management, reduce health care disparities, and enhance patient outcomes through telehealth and team-based care.","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"235-238"},"PeriodicalIF":1.1,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144506047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0